MDM2 inhibitor

DRUG CLASS:

MDM2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	RG7388 Resistant: B - Late Trials RG7388 Resistant : B	RG7388 Resistant: B - Late Trials RG7388 Resistant : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
MDM2 amplification	Sarcoma	MDM2 amplification	Sarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
TP53 wild-type	Lymphoma	TP53 wild-type	Lymphoma	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2
TP53 wild-type	Estrogen Receptor Positive Breast Cancer	TP53 wild-type	Estrogen Receptor Positive Breast Cancer	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
GATA3 mutation	Hormone Receptor Positive Breast Cancer	GATA3 mutation	Hormone Receptor Positive Breast Cancer	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib + KRT-232 Sensitive: C3 – Early Trials dabrafenib + KRT-232 Sensitive : C3	dabrafenib + KRT-232 Sensitive: C3 – Early Trials dabrafenib + KRT-232 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib + KRT-232 Sensitive: C3 – Early Trials trametinib + KRT-232 Sensitive : C3	trametinib + KRT-232 Sensitive: C3 – Early Trials trametinib + KRT-232 Sensitive : C3
TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3
TP53 wild-type	Multiple Myeloma	TP53 wild-type	Multiple Myeloma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Melanoma	TP53 wild-type	Melanoma	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3
TP53 wild-type	Salivary Gland Cancer	TP53 wild-type	Salivary Gland Cancer	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3

MDM2 inhibitor

MDM2 inhibitor

Associations(62)

Associations
(62)